Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11088146 | 0.90 | SLC18A3 (0.45) | SIGMAR1NPY1RHTTNPY2R | |
| SCHEMBL11084008 | 0.90 | SLC18A3 (0.45) | SIGMAR1NPY1RHTTNPY2R | |
| SCHEMBL11084006 | 0.90 | SLC18A3 (0.45) | SIGMAR1NPY1RHTTNPY2R | |
| SCHEMBL12716991 | 0.82 | SLC18A3 (0.48) | SIGMAR1NPY1RHTTNPY2R | |
| SCHEMBL8301747 | 0.82 | HTR1A (0.51) | SIGMAR1HTR1AGBA1NPY1RHTT | |
| SCHEMBL3176956 | 0.82 | HTR1A (0.51) | SIGMAR1HTR1AGBA1NPY1RHTT | |
| SCHEMBL2294097 | 0.79 | MAPT (0.53) | SIGMAR1GBA1ACHE | |
| SCHEMBL1318062 | 0.78 | LTA4H (0.52) | SIGMAR1NPY1RHTTNPY2R | |
| SCHEMBL8925928 | 0.78 | TACR1 (0.50) | — | |
| SCHEMBL28233337 | 0.78 | CFB (0.54) | SIGMAR1GBA1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | SIGMAR1 209/4885HTR1A 33/4885GBA1 1955/4885 |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | SIGMAR1 209/4885HTR1A 33/4885GBA1 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.